Compare Stocks: ORGO, MDXG, DBVT, and AURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.17 -0.8%	$7.11	$4.73 ▼ $9.53	$645.05M	0.41	987,360 shs	607,488 shs
DBVT DBV Technologies	$9.98 -4.4%	$13.11	$9.82 ▼ $26.18	$656.44M	-1.04	409,292 shs	558,006 shs
MDXG MiMedx Group	$4.62 +1.5%	$4.49	$3.03 ▼ $7.97	$663.21M	1.18	1.22 million shs	1.05 million shs
ORGO Organogenesis	$1.34 +3.9%	$1.71	$1.28 ▼ $7.08	$165.99M	1.27	679,566 shs	608,728 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-0.80%	+0.33%	-18.39%	-14.90%	+4.22%
DBVT DBV Technologies	-4.41%	-13.59%	-25.91%	-40.42%	-24.91%
MDXG MiMedx Group	+1.54%	-1.07%	+1.09%	+8.45%	-36.80%
ORGO Organogenesis	+3.88%	-3.25%	-21.64%	-45.75%	-68.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.17 -0.8%	$7.11	$4.73 ▼ $9.53	$645.05M	0.41	987,360 shs	607,488 shs
DBVT DBV Technologies	$9.98 -4.4%	$13.11	$9.82 ▼ $26.18	$656.44M	-1.04	409,292 shs	558,006 shs
MDXG MiMedx Group	$4.62 +1.5%	$4.49	$3.03 ▼ $7.97	$663.21M	1.18	1.22 million shs	1.05 million shs
ORGO Organogenesis	$1.34 +3.9%	$1.71	$1.28 ▼ $7.08	$165.99M	1.27	679,566 shs	608,728 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-0.80%	+0.33%	-18.39%	-14.90%	+4.22%
DBVT DBV Technologies	-4.41%	-13.59%	-25.91%	-40.42%	-24.91%
MDXG MiMedx Group	+1.54%	-1.07%	+1.09%	+8.45%	-36.80%
ORGO Organogenesis	+3.88%	-3.25%	-21.64%	-45.75%	-68.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.33	Hold	$17.50	183.63% Upside
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	385.97% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	85.53% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	223.38% Upside

Current Analyst Ratings Breakdown

Latest ORGO, MDXG, DBVT, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/15/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
8/13/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
DBVT DBV Technologies	$5.64M	111.27	N/A	N/A	$4.20 per share	2.38
MDXG MiMedx Group	$418.63M	1.61	$0.56 per share	8.21	$1.73 per share	2.67
ORGO Organogenesis	$564.17M	0.31	$0.67 per share	1.99	$2.36 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/12/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	115.53	27.18	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)

Latest ORGO, MDXG, DBVT, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	MDXG MiMedx Group	$0.0067	N/A	N/A	N/A	$69.65 million	N/A
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	16.82	16.82
DBVT DBV Technologies	N/A	3.72	3.72
MDXG MiMedx Group	0.07	5.33	4.79
ORGO Organogenesis	0.07	3.52	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
DBVT DBV Technologies	71.74%
MDXG MiMedx Group	79.15%
ORGO Organogenesis	49.57%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
DBVT DBV Technologies	1.06%
MDXG MiMedx Group	2.50%
ORGO Organogenesis	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	113	103.71 million	101.74 million	Not Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
MDXG MiMedx Group	808	145.76 million	142.12 million	Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable

ORGO, MDXG, DBVT, and AURA Headlines

Recent News About These Companies

Organogenesis Holdings stock falls 2.13 percent as Q2 revenue drops sharply

September 28, 2026 | ad-hoc-news.deA

ORGO stock gains on a fresh price snapshot

September 19, 2026 | ad-hoc-news.deA

Organogenesis (NASDAQ:ORGO) Stock Rating Upgraded by Wall Street Zen

September 19, 2026 | marketbeat.com

Organogenesis stock trades without a fresh catalyst, recent results define the picture

August 29, 2026 | ad-hoc-news.deA

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Organogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annually

August 8, 2026 | seekingalpha.com

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Organogenesis Launches New $75 Million At-The-Market Offering

August 6, 2026 | tipranks.com

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

August 6, 2026 | globenewswire.com

Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers

July 27, 2026 | quiverquant.comQ

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

July 27, 2026 | globenewswire.com

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

July 9, 2026 | globenewswire.com

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

July 6, 2026 | globenewswire.com

Organogenesis Stockholders Reelect Board and Approve Governance Items

June 16, 2026 | tipranks.com

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

June 15, 2026 | seekingalpha.com

Organogenesis Earnings Call: Deep Pain, Long Road

June 7, 2026 | theglobeandmail.com

Truist Securities initiates coverage of Organogenesis Holdings (ORGO) with hold recommendation

May 29, 2026 | msn.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 22, 2026 | finance.yahoo.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 20, 2026 | insidermonkey.com

Organogenesis (ORGO) Q1 2026 Earnings Transcript

May 8, 2026 | fool.com

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, MDXG, DBVT, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.17 -0.05 (-0.80%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$6.12 -0.05 (-0.89%)

As of 07:14 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.98 -0.46 (-4.41%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$9.74 -0.24 (-2.40%)

As of 05:33 AM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

MiMedx Group NASDAQ:MDXG

$4.62 +0.07 (+1.54%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$4.62 0.00 (0.00%)

As of 07:58 AM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Organogenesis NASDAQ:ORGO

$1.34 +0.05 (+3.88%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$1.31 -0.03 (-2.16%)

As of 08:03 AM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, MDXG, DBVT, and AURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, MDXG, DBVT, and AURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, MDXG, DBVT, and AURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, MDXG, DBVT, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

DBV Technologies NASDAQ:DBVT

MiMedx Group NASDAQ:MDXG

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, MDXG, DBVT, and AURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, MDXG, DBVT, and AURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, MDXG, DBVT, and AURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, MDXG, DBVT, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

DBV Technologies NASDAQ:DBVT

MiMedx Group NASDAQ:MDXG

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools